



04-12-07

1FW

1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Hans Josef STAUSS)	
Liquan GAO)	
Application No. 09/625,963)	Confirmation No. 8595
Filed: July 20, 2000)	
For: IMMUNOTHERAPEUTIC METHODS)	Group Art Unit: 1644
USING EPITOPES OF WT-1 AND GATA)	
Examiner: Francois P. Vandervegt)	Docket No. VOS-205 (formerly ICI-101)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP ISSUE FEE
 Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, §1.97 and §1.98, non-patent documents that may be material to the examination of this application are listed on the attached forms PTO/SB/08B. Undersigned counsel took over the representation of this application by power of attorney filed January 9, 2007, and less than thirty days before the filing of this Supplemental Information Disclosure Statement, learned that the listed references were first cited in a European opposition to a counterpart European Patent No. 1127068. Accordingly, copies of each of the listed references are enclosed along with a check in the amount of \$180.00 (37 CFR 1.17(p)). Applicants request that the listed references be considered or in the alternative be placed in the file.

The cited documents disclose numerous specific features. There has been no attempt to enumerate each and every feature disclosed by each document, however. The Examiner is requested to review these documents and to determine the extent of the materiality of the document disclosures, if any, with respect to the present invention.

The discussion of any art and the citation of any document herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular date which


may be relevant to the instant patent application, and/or that the art or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.

Applicants reserve the right to later set forth how the claimed invention is distinguished over the disclosure of any document or other art, including the disclosures of the art and documents recited herein, as well as documents that may be cited by the Examiner in rejecting a claim in the instant patent application.

The recitation herein of the art and documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

Respectfully submitted,

Dated: April 11, 2007

By 
Dolores T. Kenney (Reg. No. 31,269)

CUSTOMER NO. 02387
OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180



PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/625,963
		Filing Date	July 26, 2000
		First Named Inventor	Hans Josef STAUSS
		Art Unit	1644
		Examiner Name	Francois P. Vandervegt
Sheet 1	of 2	Attorney Docket Number	VOS-205 (formerly ICI-101)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		OHMINAMI, et al., "Establishment of WTI-Targeted CD8+ Human Cytotoxic...", Japan Journal of Clinical Immunology, 26th Annual Meeting Abstract, pages 248-249 (1998).	✓
		M. YASUKAWA, "Clinical Application of Cytotoxic T-Cell Clones," Japanese Journal of Clinical Hematology Program Abstracts, Vol. 39, No. 10, pages 880-881, (1998).	✓
		RAMMENSEE, et al., "MHC Ligands and Peptide Motifs: First Listing," Immunogenetics, Vol. 41, pages 178-228 (1995)	
		M. PARKHURST, et al., "Improved Induction of Melanoma-Reactive CTL with Peptides...", Journal of Immunology, pages 2539-2548 (1996).	
		C. TRAVERSARI, et al., "A Nonapeptide Encoded by Human Gene MAGE-1...", Journal of Experimental Medicine, Vol. 176 pages 1453-1457, November, 1992.	
		D. PARDOLL, "Cancer Vaccines," Nature Medicine Vaccines Supplement, Vol. 4, No. 5, pages 525-531, May, 1998	
		L. RIVOLTINI, et al., "Induction of Tumor-Reactive CTL from Peripheral Blood ...", The Journal of Immunology, pages 2257-2265 (1995)	
		M. GAGILARDI, et al., "Presentation of Peptides by Cultured Monocytes ...", International Immunology, Vol. 7, No. 11, pages 1741-1752 (1995)	
		E. REALI, et al., "Activation of Epitope-Specific Memory Cytotoxic T Lymphocyte Responses by Synthetic Peptides," Clin. Exp. Immunol., Vol. 105, pages 369-375 (1996).	
		W. SONG, et al., "Dendritic Cells Genetically Modified With an Adenovirus...", J. Exp. Med., Vol. 186, No. 8, pages 1247-1256, October, 1997.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (09-06)
 Approved for use through 03/31/2007. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/625,963
		Filing Date	July 26, 2000
		First Named Inventor	Hans Josef STAUSS
		Art Unit	1644
		Examiner Name	Francois P. Vandervegt
Sheet 2	of 2	Attorney Docket Number	VOS-205 (formerly ICI-101)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		D. COLE, et al., "Identification of MART-1-Specific T-Cell Receptors: T Cells Utilizing Distinct T-Cell ...," Cancer Research, Vol. 54, pages 5265-5268, October, 1994.	
		P. COULIE, "Human Tumour Antigens Recognized by T Cells: New Perspective for Anti Cancer Vaccines?" Molecular Medicine Today, pages 261-268, June, 1997.	
		N. KIENZLE, "Identification of a Cytotoxic T-Lymphocyte Response to the Novel BARF0-Protein ...," Journal of Virology, Vol. 72, No. 8, pages 6614-6620, August, 1998.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.